Lupin links with Polish firm to jumpstart Advair generic plans

Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.